While treatment with PI3Kα specific or pan-PI3K inhibitor in murine TNBC models did not improve anti-tumor response over ICI alone, the PI3K/mTOR dual inhibitor gedatolisib synergized with ICIs, leading to greater growth inhibition with increased activation of T-cell, natural killer (NK)-cell, and dendritic cell (DC) responses [37]. This evidence concerns the gene MTOR and neoplasm.